Morningstar: Maintains fair value of TONGCHENGTRAVEL (00780) at 27 Hong Kong dollars. In the long term, the proportion of international tourism revenue will exceed 15%.
The bank believes that its international operations and expanding profit margins will continue to be catalysts for long-term growth.
Morningstar released a research report stating that it maintains TONGCHENGTRAVEL (00780) fair value at 27 Hong Kong dollars. The company's third-quarter revenue increased by 10% year-on-year, mainly due to strong growth in accommodation bookings, with revenue meeting expectations; operating profit margin exceeded expectations by 100 basis points; core revenue grew by 15%. The bank believes that its international business and profit margin expansion are still catalysts for long-term growth.
The bank expects that the number of room nights at Tongcheng Hotels will increase by 23%, reflecting strong demand. The group expects core business revenue to increase by 15-20% in the fourth quarter, including the additional revenue brought by the recent acquisition of Wanda. Excluding this acquisition, the bank still expects revenue to achieve double-digit growth. The monetization rate of international tourism is around 10-15%, higher than domestic low-star hotels (5%-6%), which may indicate an increase in future profit margins. The bank predicts that in the long term, the proportion of international tourism revenue will exceed 15%.
Related Articles

Subsidiary YKYY018 of Youcare Pharmaceutical Group (688658.SH) receives FDA clinical trial approval for its nebulized inhalant.

Zhejiang Jiuzhou Pharmaceutical (603456.SH): The US FDA has approved the listing permit for the slow-release tablets of sitagliptin and metformin sustained release tablets.

Beijing Wandong Medical Technology (600055.SH) has received a medical device registration certificate.
Subsidiary YKYY018 of Youcare Pharmaceutical Group (688658.SH) receives FDA clinical trial approval for its nebulized inhalant.

Zhejiang Jiuzhou Pharmaceutical (603456.SH): The US FDA has approved the listing permit for the slow-release tablets of sitagliptin and metformin sustained release tablets.

Beijing Wandong Medical Technology (600055.SH) has received a medical device registration certificate.

RECOMMEND

Hong Kong Stock Buyback Wave Persists, 247 Listed Companies Repurchase Over HKD 150 Billion This Year
27/11/2025

Mingyu Pharmaceutical Files With HKEX: Ongoing Net Losses Since Inception, No Revenue From Commercial Product Sales
27/11/2025

“Affordability Crisis”! Consumer Confidence Falls To Second Lowest Since The Pandemic, U.S. Retail Slumps
27/11/2025


